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Dear Editor,
C
eliac disease (CD) is a chronic inflammatory 
disease  of  the  gut  occurring  in  genetically 
susceptible individuals after the ingestion of gluten. It 
is characterized by a flattened mucosa, villous atrophy, 
and crypt hyperplasia in the small intestine, by the 
classic malabsorption syndrome (diarrhea, steatorrhea, 
weight loss), or by seemingly less severe symptoms such 
as  iron  deficiency  anemia,  osteopenic  bone  disease, 
amenorrhea,  and  infertility  (1).  The  elimination  of 
gluten  from  the  diet  generally  leads  to  a  return  to 
normality of the morphological changes (2). Intestinal 
damage  is  caused  by  an  interaction  between  the 
deamidated glutamine residues of gliadin and HLA-
DQ2  (DQA1*05/DQB1*2)  or  DQ8  (DQA1*03/
DQB1*0302)  molecules  (3),  with  consequent T-cell 
response and production of autoantibodies against type 
2 transglutaminase (anti-tTG2-Ab). HLA phenotype is 
also considered the most important genetic marker of 
nonresponders to the hepatitis B (HBV) vaccination. 
In  particular,  the  immune  response  to  the  HBV 
vaccine is largely determined by the presence of the 
immunogenetic peptides via the HLA-DR and DQ 
molecules (4, 5), with the DR3-DQ2 and DR7-DQ2 
haplotypes generally having a lower response rate (6-9).
In 2000, the World Health Organization estimated 
that 2 billion people worldwide had serological evidence 
of past or present infection with HBV and that 350 
million of these people were chronically infected and at 
risk for HBV-related liver disease (10). HCV infection 
is endemic to most parts of the world, although there 
is  considerable  geographic  variation  (11).  Estimates 
indicate that 2.2% of the global population is infected 
with HCV  (12). HCV is the most common chronic 
blood-borne infection in the U.S. and is a major cause 
of  cirrhosis  and  hepatocellular  carcinoma  (13).  An 
interesting chapter in clinical practice is the possible 
association between CD and viral hepatitis. Recently, 
researchers  have  hypothesized  that  nonintestinal 
inflammatory chronic diseases, such as HBV and HCV, 
may be the immunologic trigger for the development of 
CD (14, 15). However, the association between chronic 
viral hepatitis and the development of CD is still a 
matter of debate. In a recent study, Leonardi and La 
Rosa found no cases of CD in a retrospective cohort 
of patients carrying HBV, and no CD cases appeared 
during  treatment  with  interferon  (16).  This  study, 
although limited by the small size of patients studied, is 
interesting because it may be representative of what has 
been observed in Italy. HBV prevalence in Italy is higher 
than in the rest of Europe (17), and a high prevalence of 
CD is estimated as well (18). A more interesting question 
is: if it does not seem to be an association between 
CD and viral hepatitis in Italy, what is happening in 
other regions of the world that have a high incidence 
of viral hepatitis (19-21) and an increased incidence of 
CD (22, 23)? Until further, large, epidemiological studies 
investigate this question, the answer is still open. 
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We  have  more  answers  about  what  happens 
in  coeliacs  after  vaccination.  Mass  immunization 
of  the  population  has  been  recommended  by  the 
World Health organization since 1991 (24), and it is 
generally  performed  in  12-year-old  schoolchildren 
(25). We know that CD patients have a lower rate of 
immunization after HBV vaccination (26, 27). We do 
not know if CD will increase with the actual rate of 
vaccination. This may be a problem for the public 
health system because a great deal of young people 
may be at high risk of contracting HBV due to a lack 
of immunization. In a fine paper published in 2008, 
Nemes et al. demonstrated that the response to HBV 
vaccination in CD patients is related to the response 
to a gluten-free diet (28). In fact, an adequate vaccine 
response  to  HBV  was  found  in  coeliacs  compliant 
with (Gluten-Free Diets) GFD, whereas nonresponse 
was a sign of undiagnosed CD or a lack compliance 
to GFD (28). Surprisingly, Nemes et al. did not find 
any association between nonresponse and HLA-DQ2 
or DQ8 status (28). These results have been recently 
confirmed by Ertem et al., who found that response to 
HBV vaccine in children with CD who are compliant 
with GFD did not differ from the response in a healthy 
population (29). Therefore, until new epidemiological 
data shed light on the possible association between 
CD and HBV infection, good advices seems to be
1. to screen for CD in schoolchildren before HBV 
vaccination;
2.  to  obtain  optimal  compliance  to  GFD  in  CD 
patients before HBV vaccination to reduce the 
risk of unresponsiveness;
3. to revaccinate during a well-controlled GFD in 
order to maintain a high level of immunization.
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